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ST ‑segment elevation MI due to stent throm‑
bosis within the RCA, which was successful‑
ly treated with manual aspiration thrombec‑
tomy followed by balloon angioplasty (Figure 1C). 
Dual antiplatelet therapy was modified to ace‑
tylsalicylic acid (75 mg once daily) and ticagre‑
lor (90 mg twice daily). Ten months after stent 
thrombosis, he was admitted again due to in‑
ferior wall ST ‑segment elevation MI. Urgent 
coronary angiography revealed another stent 
thrombosis within the RCA (Figure 1d). PCI was 
performed with aspiration thrombectomy and 
glycoprotein IIb/IIIa inhibitor was adminis‑
tered intracoronary, followed by drug ‑eluting 
stent implantation (Xience PRO, 3.75 × 48 mm) 
at 18 atm. An optimal result was achieved with 
post ‑dilatation with noncompliant balloon, 
3.75 × 20 mm, at 20 atm (Figure 1d). No complica‑
tions were observed and left ventricular ejection 
Type 1 neurofibromatosis (NF1), also known as 
von Recklinghausen disease, is an autosomal 
dominant multisystem genetic disorder.1 Vascu‑
lar manifestations of NF1 in coronary arteries 
include aneurysmal and stenotic lesions, which 
may predispose to thrombotic mass formation, 
and eventually, myocardial infarction (MI).2 
The appearance of recurrent stent thrombosis 
in patients with NF1 has not been reported so far.
A 55‑year ‑old man was admitted to the emer‑
gency department due to severe chest pain last‑
ing 4 hours. He was diagnosed with NF1 in child‑
hood and had typical massive neurofibromas on 
the skin (Figure 1A) and a benign tumor in the brain 
(Figure 1B). He underwent elective percutaneous 
coronary intervention (PCI) of the left ascend‑
ing artery in 2014 and the right coronary ar‑
tery (RCA) in 2015 with drug ‑eluting stents 
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 Figure 1 A – a typical manifestation of type 1 neurofibromatosis with massive neurofibromas on the skin of the chest and back; B – small tumor (16 mm) within 
the right temporal lobe—neurofibroma (arrow); C – coronary angiography during the first stent thrombosis of the right coronary artery: baseline (top) and final 
(bottom) images; D – coronary angiography during the second stent thrombosis of the right coronary artery: baseline (top) and final (bottom) images
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fraction at discharge was 41%. Dual antiplatelet 
therapy was sustained with acetylsalicylic acid 
and ticagrelor, as the neurologist denied the ad‑
dition of oral anticoagulation due to brain tu‑
mor. Unfortunately, the patient suddenly died 
1 year after the last PCI. Stent thrombosis could 
have been the cause of death, but neither angi‑
ography nor autopsy was performed.
So far, PCIs in patients with neurofibroma‑
tosis have been rarely reported. The presence of 
large coronary aneurysms is postulated as a rea‑
son for acute MI in this population. However, 
the pathophysiology of vascular pathologies in 
neurofibromatosis is multifactorial:3 from dis‑
turbed smooth muscle migration to impaired 
vascular tissue histogenesis and healing, which 
could be crucial after stent implantation and 
may explain repeated stent thrombosis despite 
optimal antiplatelet treatment in our patient.
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